Skip to main content

Legend Biotech Corporation (LEGN) Stock Forecast

Data as of Aug 4, 2026

Healthcare · Current price $19.05 (+0.21%)

Consensus Target
$58.00
Upside
+184.1%
Analysts
11
Rating
Buy(2.09)

Price Target Range

Low $24.00Consensus $58.00High $75.00
▲ Current $19.05

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy5
Hold1
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

LEGN vs Sector & Market

MetricLEGNHealthcare AvgLarge Cap Avg
Analyst Rating2.092.252.42
Analyst Count11819
Target Upside+184.1%+16316.0%+17.1%
P/E Ratio-14.653.2044.37

Revenue Estimates

PeriodLowAvgHigh#
2027-03-31$383M$402M$429M4
2027-06-30$403M$424M$452M6
2027-09-30$428M$450M$480M4
2027-12-31$681M$716M$764M7
2028-03-31$414M$435M$464M3
2028-06-30$423M$444M$474M5
2028-09-30$878M$923M$984M3
2028-12-31$961M$1.01B$1.08B6

EPS Estimates

PeriodLowAvgHigh#
2027-03-31$0.16$0.18$0.192
2027-06-30$0.19$0.20$0.221
2027-09-30$0.25$0.27$0.301
2027-12-31$0.34$0.36$0.392
2028-03-31$0.16$0.17$0.193
2028-06-30$0.18$0.19$0.212
2028-09-30$0.35$0.37$0.402
2028-12-31$0.78$0.84$0.913

Frequently Asked Questions

What is the analyst consensus for LEGN?

The consensus among 11 analysts covering Legend Biotech Corporation (LEGN) is Buy with an average price target of $58.00.

What is the highest price target for LEGN?

The highest analyst price target for LEGN is $75.00.

What is the lowest price target for LEGN?

The lowest analyst price target for LEGN is $24.00.

How many analysts cover LEGN?

11 analysts have issued ratings for Legend Biotech Corporation in the past 12 months.

Is LEGN a buy or sell right now?

Based on 11 analyst ratings, LEGN has a consensus rating of Buy (2.09/5) with a +184.1% upside to the consensus target of $58.00.

What are the earnings estimates for LEGN?

Analysts estimate LEGN will report EPS of $0.18 for the period ending 2027-03-31, with revenue estimated at $402M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.